Credit Suisse Cuts The Medicines Co. (MDCO) PT to $28 Following Hospira Patent Litigation Outcome
Tweet Send to a Friend
Credit Suisse keeps The Medicines Company (Nasdaq: MDCO) at Neutral and lowers its price target from $35 down to $28 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
